The current treatment for Asherman syndrome is limited and not very effective. The aim of this review is to summarize the most recent evidence for stem cells in the treatment of Asherman syndrome. The advent of stem cell therapy has propagated experimentation on mice and humans as a novel treatment. The consensus is that the regenerative capacity of stem cells has demonstrated improved outcomes in terms of fertility and fibrosis in both mice and humans with Asherman syndrome. Stem cells have effects on tissue repair by homing to the injured site, recruiting other cells by secreting chemokines, modulating the immune system, differentiating into other types of cells, proliferating into daughter cells, and potentially having antimicrobial activity. The studies reviewed examine different origins and administration modalities of stem cells. In preclinical models, therapeutic systemic injection of stem cells is more effective than direct intrauterine injection in regenerating the endometrium. In conjunction, bone marrow-derived stem cells have a stronger effect on uterine regeneration than uterine-derived stem cells, likely due to their broader differentiation potency. Clinical trials have demonstrated the initial safety and effectiveness profiles of menstrual, bone marrow, umbilical cord, and adipose tissue-derived stem cells in resumption of menstruation, fertility outcomes, and endometrial regeneration.

中文翻译：

---

阿舍曼综合征干细胞疗法的最新进展。

当前用于阿舍曼综合症的治疗是有限的并且不是非常有效。这篇综述的目的是总结干细胞治疗阿舍曼综合征的最新证据。干细胞疗法的出现已经在小鼠和人类上传播了作为一种新疗法的实验方法。普遍的共识是，在具有Asherman综合征的小鼠和人类中，干细胞的再生能力在生育能力和纤维化方面已显示出改善的结果。干细胞通过归巢至受损部位，通过分泌趋化因子募集其他细胞，调节免疫系统，分化为其他类型的细胞，增殖为子代细胞并可能具有抗菌活性，从而对组织修复产生影响。审查的研究检查了干细胞的不同来源和给药方式。在临床前模型中，干细胞的治疗性全身注射在子宫内膜再生方面比直接宫内注射更有效。结合起来，骨髓干细胞对子宫再生的作用比子宫干细胞对子宫的作用强，这可能是由于它们的分化潜能更广。临床试验已证明月经，骨髓，脐带和脂肪组织来源的干细胞在恢复月经，生育结局和子宫内膜再生方面的初始安全性和有效性。可能是由于它们具有更广泛的分化潜能。临床试验已证明月经，骨髓，脐带和脂肪组织来源的干细胞在恢复月经，生育结局和子宫内膜再生方面的初始安全性和有效性。可能是由于它们具有更广泛的分化潜能。临床试验已证明月经，骨髓，脐带和脂肪组织来源的干细胞在恢复月经，生育结局和子宫内膜再生方面的初始安全性和有效性。